Analyst Ratings For NASDAQ:DCPH – Deciphera Pharmaceuticals (NASDAQ:DCPH)
Today, JPMorgan Chase & Co. raised its price target on NASDAQ:DCPH – Deciphera Pharmaceuticals (NASDAQ:DCPH) to per share.
Some recent analyst ratings include
- 10/23/2017-Nomura initiated coverage with a Buy ➝ Buy rating.
- 10/23/2017-Piper Jaffray Companies initiated coverage with a Overweight ➝ Overweight rating.
- 10/23/2017-Instinet initiated coverage with a Buy rating.
- 10/23/2017-JMP Securities initiated coverage with a Mkt Outperform ➝ Outperform rating.
Recent Insider Trading Activity For NASDAQ:DCPH – Deciphera Pharmaceuticals (NASDAQ:DCPH)
NASDAQ:DCPH – Deciphera Pharmaceuticals (NASDAQ:DCPH) has insider ownership of 20.61% and institutional ownership of 47.68%.
- On 10/2/2017 New Leaf Venture Management Ii, Major Shareholder, bought 375,000 with an average share price of $17.00 per share and the total transaction amounting to $6,375,000.00.
Recent Trading Activity for NASDAQ:DCPH – Deciphera Pharmaceuticals (NASDAQ:DCPH)
Shares of NASDAQ:DCPH – Deciphera Pharmaceuticals closed the previous trading session at 29.00 up +3.09 11.93% with 29.584999084472656 shares trading hands.